Reviewing Fortrea (FTRE) & Its Competitors

Fortrea (NASDAQ:FTREGet Free Report) is one of 47 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Fortrea to related companies based on the strength of its earnings, risk, valuation, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for Fortrea and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea 1 5 5 1 2.50
Fortrea Competitors 308 1205 2105 33 2.51

Fortrea presently has a consensus target price of $32.30, indicating a potential upside of 27.12%. As a group, “Medical laboratories” companies have a potential upside of 24.46%. Given Fortrea’s higher probable upside, research analysts clearly believe Fortrea is more favorable than its rivals.

Earnings and Valuation

This table compares Fortrea and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fortrea $3.11 billion -$3.40 million -18.28
Fortrea Competitors $976.84 million -$121.96 million 4.68

Fortrea has higher revenue and earnings than its rivals. Fortrea is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Fortrea and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortrea -4.11% 4.76% 1.87%
Fortrea Competitors -3,338.19% -1,358.92% -41.93%

Institutional & Insider Ownership

47.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 0.1% of Fortrea shares are owned by insiders. Comparatively, 18.8% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Fortrea beats its rivals on 7 of the 11 factors compared.

Fortrea Company Profile

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.